Have you cited CABT-L509 in a publication? Let us know and earn a reward for your research.
Background
Neutrophil elastase (NE) is the main protease from neutrophil primary granules involved in microbicidal activities. It is a serine protease that breaks down a variety of substances such as elastin, collagen and fibronectin. NE is an important factor that promotes inflammation, is bactericidal and shortens the inflammatory process, and it also regulates tumor growth by promoting tumor metastasis and tumor microenvironment remodeling. However, under certain conditions NE has a tumor-killing effect and promotes other diseases such as pulmonary ventilation dysfunction. The level and activity of NE reflects the state and severity of the disease.
Following the onset of inflammation, neutrophils rapidly accumulate toward the site of inflammation through a multistep adhesion cascade, and upon arrival at the site of inflammation, they fight pathogens through a series of processes, including participation in the phagocytosis of microorganisms, production of ROS, secretion of NE, and formation of neutrophil extracellular traps (NETs). NE is a weapon for neutrophils to destroy pathogenic microorganisms and synergizes with neutrophils to digest microorganisms. NE also prevents the degradation of toxic substances released by bacteria, and exposure to cytokines, chemokines, or bacterial products can lead to the accumulation of NE and anti-infective factors at the site of infection. Damaged basement membranes release laminin fragments that promote neutrophil migration and antioxidant factor recruitment, thereby accelerating the inflammatory process.
Figure 1. The specific process of the anti-infection effect of NE (Source: Zeng W, et al. 2023)
NE is also recognized as a positive promoter of inflammation and is present in the airways of patients with various lung diseases. NE exposure induces airway remodeling and interrupts epithelial repair, which amplifies protease activity and inflammation within the airways by directly activating inflammation through increased cytokine expression and release, and indirectly activating inflammation by triggering extracellular traps and exosome release. CXCL8 increases neutrophil release of NE, which degrades some proteases such as secretory leukocyte protease inhibitor (SLPI) and tissue inhibitor of metalloproteinases-1 (TIMP-1) and activates some proteases such as the neutrophil metalloproteinase gelatinase, which further sustains large-scale proteolytic inflammation.
Figure 2. NE mediates pulmonary ventilation dysfunction (Source: Zeng W, et al. 2023)
Alternative Names
anti Human NE polyclonal antibody
References
1. Zeng W, et al. Neutrophil elastase: From mechanisms to therapeutic potential. J Pharm Anal. 2023 Apr;13(4):355-366.
2. Voynow JA, et al. Neutrophil Elastase and Chronic Lung Disease. Biomolecules. 2021 Jul 21;11(8):1065.
My Review for Sheep anti Human Neutrophil Elastase polyclonal antibody [HRP]
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
References
Conditional Expression of Mutant ELANE Produces Unfolded Protein Response but Fails to Promote Cell Death or Differentiation Block: What Is the Mechanism for Severe Congenital Neutropenia?
Severe congenital neutropenia (SCN) is characterized by low blood neutrophil counts, early bacterial infections, and risk of leukaemia development. As yet, no population-based incidence estimates of SCN have been reported. Children less than 16 years of age with SCN were sought in Sweden during the 20-year period 1987-2006 by a questionnaire to all Swedish Departments of Paediatrics and by reviewing the Swedish Health and Welfare Statistical Databases. Thirty-two patients were diagnosed with congenital neutropenia during this period. All received treatment with recombinant granulocyte-colony stimulating factor (G-CSF). Twenty-one patients were diagnosed as SCN or probable SCN, corresponding to 1.0 per 100 000 live births. Nine (43%) had ELANE mutations, four (19%) HAX1 mutations and eight (38%) were children with disease of unknown genetic aetiology. Four out of 21 patients (19%) developed myelodysplastic syndrome/leukaemia and three (14%) died, all with leukaemia. The cumulative incidence of myelodysplastic syndrome/leukaemia was 31%. The observed incidence of SCN in this population-based study was higher than previously estimated, possibly because genetic testing now can identify SCN cases previously thought to be idiopathic or benign neutropenia. The risk of developing myelodysplastic syndrome/leukaemia is considerable. ELANE mutations are the most commonly identified genetic defects.